20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Serum carbohydrate antigen (CA 19-9) is the most common tumor marker assessed in pancreatic cancer patients; nevertheless few articles have comprehensively evaluated the evidence for its utility in pancreatic cancer management.

          Related collections

          Author and article information

          Journal
          J Gastrointest Oncol
          Journal of gastrointestinal oncology
          2219-679X
          2078-6891
          Jun 2012
          : 3
          : 2
          Article
          jgo-03-02-105
          10.3978/j.issn.2078-6891.2011.021
          3397644
          22811878
          c3fc927c-67cc-4077-9fb6-aa84fd6a3abf
          History

          CA 19-9,Pancreatic cancer,diagnosis,prognosis,recurrence,resectability,screening,tumor markers

          Comments

          Comment on this article